Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals
Portfolio Pulse from Benzinga Insights
Six analysts have recently updated their ratings on Jazz Pharmaceuticals (NASDAQ:JAZZ), with a mix of bullish and bearish sentiments. The average 12-month price target is now $189.33, down from $198.67, with a high estimate of $225 and a low of $135. Analysts from Baird, Truist Securities, Needham, UBS, and RBC Capital have provided various ratings and price target adjustments. Jazz Pharmaceuticals, known for its treatments for sleeping disorders and oncology, has shown impressive revenue growth and net margin but carries a high debt-to-equity ratio.
January 03, 2024 | 12:00 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Analysts have mixed opinions on Jazz Pharmaceuticals, with recent price target adjustments reflecting a slightly bearish sentiment. The average price target has decreased, and the company's high debt-to-equity ratio may concern investors.
The decrease in the average price target suggests a bearish outlook from analysts, which could lead to short-term negative sentiment among investors. The company's financials show strength in revenue growth and profitability, but the high debt-to-equity ratio is a potential risk factor that might weigh on the stock price.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100